New approach to treat advanced melanoma
Biopharmaceutical company Kiadis Pharma announces that it has successfully completed treatment of the last patient on its ATIR phase I/II clinical trial. ATIR, a donor lymphocyte cell based product, is under development to prevent acute Graft versus Host Disease (GvHD) and allow early immune reconstitution following a mismatched bone marrow transplantation. Nineteen end stage
Full Post: Kiadis Pharma announces positive results for ATIR in mismatched bone marrow transplantation
Skin cancer patient Debra Gardocki receives an injection from oncologist Dr. Sanjiv Agarwala as part of a study exploring a new approach to treat advanced melanoma — an often fatal form of cancer for which there are limited effective treatment options.
The study — which is taking place at up to 25 centers across the United States and Canada — includes combining a therapeutic cancer vaccine along with more traditional immune therapies.
Therapeutic cancer vaccines are uniquely designed to stimulate the body’s own defenses — the immune system — to find and fight cancer cells. The vaccine is designed to treat existing cancer rather than prevent it from developing. Sanofi Pasteur, the vaccines division of sanofi-aventis Group, has invested more than five years of work to develop this vaccine regimen and bring it to clinical trials.
The European Patent Court in Munich, Germany has ruled in favor of Advaxis Incorporated and reversed a patent challenge made by Anza Therapeutics, Inc., formerly Cerus Corp. The Court’s ruling is final and can not be appealed. The challenge was made against elements of a patent filed, and subsequently published in 1994, by Dr. Yvonne
Full Post: Advaxis wins European patent case involving Lovaxin-C vaccine
Molecules of sugar sitting on the surface of cancer cells are keys to the development of a new vaccine aimed at both treating and stopping the spread of certain types of cancers called carcinomas, which include prostate, breast, ovarian and lung, among others. Armed with a new two-year grant for $600,000 from the Gateway for
Full Post: Novel low-cost immunotherapy for cancer cells
GeoVax Labs, Inc. has announced that the launch of its Phase 2a Human Vaccine Trials will take place in twelve sites across North and South America. These trials are conducted in collaboration with The National Institutes of Health (NIH), and the HIV Vaccine Trials Network (HVTN). “It is of significant importance to report this major
Full Post: GeoVax’s HIV/AIDS human vaccine trials to begin in North and South America
A pediatric vaccine with University of Rochester roots has proven to be highly successful at reducing cases of bacterial meningitis across all age groups.That is the conclusion of a seven-year study, the results of which appeared today in the New England Journal of Medicine. “This is a very effective vaccine and a textbook example of
Full Post: Pediatric vaccine propels sharp drop in meningitis cases
A new vaccine principle is being developed by scientists at the University of Copenhagen which - if it works to its full expected potential - could help to save millions of lives and revolutionise current vaccine technology. The ‘InVacc’ platform, as it is known, represents an advance on the original DNA vaccines and generates new
Full Post: New vaccine principle delivers stronger and faster immune response